Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutathera for Carcinoid Heart Disease
NCT04039516Phase 2Unknown
- Sponsor
- King's College Hospital
- Start
- Oct 2020
- Primary completion
- Nov 2024
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised, open-label trial in carcinoid heart disease (CHD), Carcinoid Syndrome (CS) and Neuroendocrine Neoplasm (NEN) comparing Lutathera + SSA with Best Supportive Care (SSA) (2 arms). Primary endpoint: Rate of progression of moderate carcinoid heart disease at 5 years. Status: unknown.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
carcinoid heart disease (CHD)Carcinoid Syndrome (CS)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT04039516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04039516.